Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
The Prostate|July 2, 2026
The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPCKohei Hashimoto, Kouji Izumi, Takashi Shima, et al.
The Prostate|April 4, 2025
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE StudyTakehiko Okamura, Kouji Izumi, Satoshi Kurokawa, et al.
European Urology Open Science|July 11, 2022
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled TrialKouji Izumi, Takashi Shima, Koji Mita, et al.
The Prostate|September 20, 2024
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCaNobumichi Tanaka, Kouji Izumi, Yasushi Nakai, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 20, 2026
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCaSeiji Hoshi, Kouji Izumi, Satoru Meguro, et al.
Cancers|February 10, 2024
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCaKoji Mita, Kouji Izumi, Akihiro Goriki, et al.
Pageof 4